- Spirovant

Leading the Revolution in Treating Genetic Lung Diseases

Spirovant Sciences is developing novel gene therapies for cystic fibrosis and other pulmonary diseases. We are the only company advancing programs with both AAV and lentivirus vectors.

Spirovant CEO Joan Lau Selected EY Entrepreneur of The Year® in Greater Philadelphia

13 Oct , 2020   Press Releases

Spirovant Sciences CEO Joan Lau selected to receive the Ernst & Young LLP (EY US) Entrepreneur of The Year 2020 Award in Greater Philadelphia by an independent panel of judges.

Spirovant CEO Joan Lau Selected as a Woman of Distinction by Philadelphia Business Journal

7 Oct , 2020   Press Releases

Spirovant announces that CEO Joan Lau, PhD, has been named a 2020 Woman of Distinction by the Philadelphia Business Journal. The award will be presented in a virtual ceremony on November 12 at 11 am.

FDA Grants Spirovant Sciences Orphan Drug and Rare Pediatric Disease Designations for SPIRO-2101 for Treatment of Cystic Fibrosis

24 Sep , 2020   Press Releases

Spirovant announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease Designations to its lead product candidate, SPIRO-2101, for the treatment of cystic fibrosis.